Patient advocates, industry leaders, medical researchers, government officials, and investors will join together in Bethesda, MD, on Oct. 7 – 9 for the 3rd annual U.S. Conference on Rare Diseases and Orphan Products.
“With the implementation of the Affordable Care Act and FDA Safety and Innovation Act, these are important times for the rare disease communityâ€
Sponsored by NORD (the National Organization for Rare Disorders) and DIA (the Drug Information Association), this major event brings together all stakeholders in the rare disease community to address shared goals, concerns, challenges and opportunities.
This year, the conference will focus specifically on today’s changing health care environment, addressing questions such as: What effect will the implementation of the Affordable Care Act have on rare disease patients? What is the investment outlook for orphan product development? And what will our health care system look like in the future?
“With the implementation of the Affordable Care Act and FDA Safety and Innovation Act, these are important times for the rare disease community,†said NORD President and CEO Peter L. Saltonstall. “This conference provides an opportunity to share our various perspectives and collaborate in ways that are absolutely essential for the millions of Americans living with rare diseases.â€
The conference, which is hosted in collaboration with the U.S. Food and Drug Administration (FDA) and EURORDIS (Rare Diseases Europe), will include keynote, plenary and smaller group sessions. Plenary sessions will open a dialogue on topics of shared interest among medical researchers, industry thought leaders, patient organizations, government officials and investors.
Small group sessions will be organized around four central themes: Research and Regulation, Access and Reimbursement, the Role of the Patient in the Research and Regulatory Process, and Implementation of the Affordable Care Act.